Shots:
The US FDA has granted full approval to Vetmedin chewable tablets (pimobendan) & Vetmedin oral solution for the delay of onset of CHF in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD)
Approval was based on the 2 multi-site studies, with the EPIC trial showing Vetmedin delayed CHF onset or cardiac-related death…
Shots:
The USDA has granted Befrena (Tirnovetmab) for Canine Allergic and Atopic Dermatitis, expected to launch in H1’26
Befrena (mAb) is an anti-IL31 injection for dogs, treats allergic and atopic dermatitis every 6–8 wks.
In September, the FDA approved changes to Zenrelia (ilunocitinib tablets) US label, eliminating the fatal vaccine-induced disease risk, Elanco announced
Ref:…
Shots:
The US FDA has granted conditional approval to Elanco's Credelio Quattro-CA1 (lotilaner, moxidectin, praziquantel, & pyrantel) for the treatment of infestations caused by New World screwworm larvae (myiasis) in dogs
Approval was based on a study showing that oral lotilaner achieved 100% efficacy against New World screwworm (Cochliomyia hominivorax) larvae within 24hrs. at the…
Shots:
The EC has approved Lenivia (Q3W) for the reduction of pain associated with osteoarthritis in dogs
Lenivia showed increased mobility & decreased pain after a single administration in a 9mos. field study, along with favorable safety in dogs
Lenivia, a monoclonal antibody targeting NGF, is designed to provide longer-lasting pain relief in osteoarthritis by…
Shots:
RION has launched RION Vet, a veterinary biotechnology subsidiary, with exclusive global rights to RION’s exosome-based therapeutic platform for animal health
RION Vet is developing ePEP-01, a cell-free, shelf-stable platelet-derived biologic, for equine musculoskeletal disorders, which was evaluated in over 50 horses for >4yrs., showing improvement in lameness, with favorable safety
RION Vet leverages…
Shots:
Dechra has launched Solovecin (cefovecin sodium) for the treatment of skin infections in dogs & cats across the US
Solovecin treats skin infections in dogs (secondary superficial pyoderma, abscesses, & wounds) caused by S. intermedius & S. canis, & in cats (wounds & abscesses) caused by susceptible strains of P. multocida
Solovecin, a long-acting…
Shots:
Phibro Animal Health has launched Restoris piezoelectric dental gel for the treatment & support of long-term oral health in dogs with periodontal disease in the US
Laboratory & clinical studies showed Restoris reduced periodontal pocket depth & promoted alveolar bone regeneration around treated teeth within 30 days
Restoris is applied into periodontal pockets via…
Shots:
The CVMP has recommended Lenivia for the reduction of pain associated with osteoarthritis in dogs, with EC’s decision expected in Q4’25. Also, a commercial launch in the EU is planned for 2026
Lenivia showed increased mobility & decreased pain after a single administration in a 9mos. field study, along with favorable safety in dogs…
Shots:
Phibro Animal Health has entered into a licensing agreement with Lighthouse Pharmaceuticals to develop & commercialize a therapeutic asset targeting periodontal health in companion animals
As per the agreement, Phibro will obtain exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma’s proprietary compound for canine periodontal care, though financial terms were not disclosed
The…
Shots:
PetPace has launched an Epilepsy Insights module to deliver low-latency, data-driven insights on epileptic events in dogs; available for beta testing in dogs with a confirmed epilepsy diagnosis
The Epilepsy Insights module is powered by the PetPace smart collar & uses AI as well as ML to manage canine epilepsy through continuous monitoring & automated…

